1
|
Chen Y, Huang L, Wang S, Liu T, Wu Y, Li JL, Li M. WAP four-disulfide core domain protein 2 promotes metastasis of human ovarian cancer by regulation of metastasis-associated genes. J Ovarian Res 2017; 10:40. [PMID: 28679402 PMCID: PMC5499000 DOI: 10.1186/s13048-017-0329-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 04/24/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND WAP four-disulfide core domain protein 2 (WFDC2) shows a tumor-restricted upregulated pattern of expression in ovarian cancer. METHODS In this study, we evaluated the role of WFCD2 in tumor mobility, invasion and metastasis of ovarian cancer in clinical tissue and in ovarian cancer cells, both in vitro and in vivo. RESULTS Our results revealed WFCD2 was overexpressed in ovarian tissues, and the expression level of WFCD2 was associated with metastasis and lymph node metastasis. Higher expression of WFCD2 was also observed in aggressive HO8910-PM cells than in HO8910 cells, and WFCD2 knockdown halted cell migration, invasion, tumorigenicity and metastasis in ovarian cancer cells, both in vitro and in vivo. Knockdown of WFDC2 induced the down-regulation of ICAM-1, CD44, and MMP2. CONCLUSION In summary, our work demonstrates that WFCD2 promotes metastasis in ovarian cancer. These findings suggest that WFCD2 plays a critical role in promoting metastasis and may constitute a potential therapeutic target of ovarian cancer.
Collapse
Affiliation(s)
- Yao Chen
- School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.,State Key Laboratory of Organ Failure, Guangdong Provincial Key Laboratory of Tropical Disease Research, Southern Medical University, Guangzhou, 510515, China.,Institute of Antibody Engineering, Southern Medical University, 1023 Shatainan Road, Guangzhou, 510515, China
| | - Liping Huang
- Obstetrics and Gynecology Center, Nanfang Hospital, Guangzhou, 510515, China
| | - Suihai Wang
- Institute of Antibody Engineering, Southern Medical University, 1023 Shatainan Road, Guangzhou, 510515, China
| | - Tiancai Liu
- Institute of Antibody Engineering, Southern Medical University, 1023 Shatainan Road, Guangzhou, 510515, China
| | - Yingsong Wu
- Institute of Antibody Engineering, Southern Medical University, 1023 Shatainan Road, Guangzhou, 510515, China.
| | - Ji-Liang Li
- Institute of Antibody Engineering, Southern Medical University, 1023 Shatainan Road, Guangzhou, 510515, China. .,Department of Oncology, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
| | - Ming Li
- School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China. .,State Key Laboratory of Organ Failure, Guangdong Provincial Key Laboratory of Tropical Disease Research, Southern Medical University, Guangzhou, 510515, China. .,Institute of Antibody Engineering, Southern Medical University, 1023 Shatainan Road, Guangzhou, 510515, China.
| |
Collapse
|
2
|
Truong A, Yip C, Paye A, Blacher S, Munaut C, Deroanne C, Noel A, Sounni NE. Dynamics of internalization and recycling of the prometastatic membrane type 4 matrix metalloproteinase (MT4-MMP) in breast cancer cells. FEBS J 2016; 283:704-22. [DOI: 10.1111/febs.13625] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Revised: 12/03/2015] [Accepted: 12/10/2015] [Indexed: 02/06/2023]
Affiliation(s)
- Alice Truong
- Laboratory of Tumor and Development Biology; Groupe Interdisciplinaire de Génoprotéomique Appliquée-Cancer (GIGA-Cancer); University of Liège; Belgium
| | - Cassandre Yip
- Laboratory of Tumor and Development Biology; Groupe Interdisciplinaire de Génoprotéomique Appliquée-Cancer (GIGA-Cancer); University of Liège; Belgium
| | - Alexandra Paye
- Laboratory of Tumor and Development Biology; Groupe Interdisciplinaire de Génoprotéomique Appliquée-Cancer (GIGA-Cancer); University of Liège; Belgium
| | - Silvia Blacher
- Laboratory of Tumor and Development Biology; Groupe Interdisciplinaire de Génoprotéomique Appliquée-Cancer (GIGA-Cancer); University of Liège; Belgium
| | - Carine Munaut
- Laboratory of Tumor and Development Biology; Groupe Interdisciplinaire de Génoprotéomique Appliquée-Cancer (GIGA-Cancer); University of Liège; Belgium
| | - Christophe Deroanne
- Laboratory of Connective Tissues Biology; GIGA-Cancer; University of Liège; Belgium
| | - Agnès Noel
- Laboratory of Tumor and Development Biology; Groupe Interdisciplinaire de Génoprotéomique Appliquée-Cancer (GIGA-Cancer); University of Liège; Belgium
| | - Nor Eddine Sounni
- Laboratory of Tumor and Development Biology; Groupe Interdisciplinaire de Génoprotéomique Appliquée-Cancer (GIGA-Cancer); University of Liège; Belgium
| |
Collapse
|
3
|
Paye A, Truong A, Yip C, Cimino J, Blacher S, Munaut C, Cataldo D, Foidart JM, Maquoi E, Collignon J, Delvenne P, Jerusalem G, Noel A, Sounni NE. EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP. Cancer Res 2014; 74:6758-70. [DOI: 10.1158/0008-5472.can-13-2994] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
De Amicis F, Perri A, Vizza D, Russo A, Panno ML, Bonofiglio D, Giordano C, Mauro L, Aquila S, Tramontano D, Andò S. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines. J Cell Physiol 2013; 228:2054-62. [PMID: 23553645 DOI: 10.1002/jcp.24372] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Accepted: 03/20/2013] [Indexed: 01/14/2023]
Abstract
Well-differentiated papillary and follicular thyroid carcinoma are the most frequent types of thyroid cancer and the prognosis is generally favorable however, a number of patients develops recurrences. Epigallocatechin-3-gallate (EGCG), a major catechin in green tea, was shown to possess remarkable therapeutic potential against various types of human cancers, although data on thyroid cancer cells are still lacking. The aim of this study was to investigate the effect of EGCG on the proliferation and motility of human thyroid papillary (FB-2) and follicular (WRO) carcinoma cell lines. Our results demonstrate that EGCG (10, 40, 60 μM) treatment inhibited the growth of FB-2 and WRO cells in a dose-dependent manner. These changes were associated with reduced cyclin D1, increased p21 and p53 expression. Furthermore, EGCG suppressed phosphorylation of AKT and ERK1/2. In addition EGCG treatment results in reduction of cell motility and migration. Changes in motility and migration in FB-2 were associated with modulation in the expression of several proteins involved in cell adhesion and reorganization of actin cytoskeleton. After 24 h EGCG caused an increase of the E-cadherin expression and a concomitant decrease of SNAIL, ZEB and the basic helix-loop-helix transcription factor TWIST. Besides expression of Vimentin, N-cadherin and α5-integrin was down-regulated. These data well correlate with a reduction of MMP9 activity as evidenced by gelatin zymography. Our findings support the inhibitory role of EGCG on thyroid cancer cell proliferation and motility with concomitant loss of epithelial-to-mesenchymal cell transition markers.
Collapse
|
5
|
Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an immunocytochemical study. BONE MARROW RESEARCH 2012; 2012:259351. [PMID: 23227342 PMCID: PMC3513718 DOI: 10.1155/2012/259351] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/21/2012] [Accepted: 10/18/2012] [Indexed: 01/06/2023]
Abstract
Matrix metalloproteinase-2 (MMP-2) is important in the dissemination and invasion of tumor cells and activates angiogenesis. We present an immunocytochemical study of MMP-2 expression in circulating prostate cells (CPCs), disseminated tumor cells (DTCs), and micrometastasis (mM) in bone marrow of men with prostate cancer. Methods and Patients. Tumor cells were identified with anti-PSA immunocytochemistry. Positive samples underwent processing with anti-MMP-2, its expression was compared with Gleason score, concordance of expression, and metastatic and nonmetastatic disease. Results. 215 men participated, CPCs were detected in 62.7%, DTCs in 62.2%, and mM in 71.4% in nonmetastatic cancer; in metastatic cancer all had CPCs, DTCs, and mM detected. All CPCs and DTCs expressed MMP-2; in mM MMP-2 expression was positively associated with increasing Gleason score. MMP-2 expression in CPCs and DTCs showed concordance. In low grade tumors, mM and surrounding stromal cells were MMP-2 negative, with variable expression in high grade tumors; in metastatic disease, both mM and stromal cells were MMP-2 positive. Conclusions. CPCs and DTCs are different from mM, with inhibition of MMP-2 expression in mM of low grade tumors. With disease progression, MMP-2 expression increases in both mM and surrounding stromal cells, with implications for the use of bisphosphonates or MMP-2 inhibitors.
Collapse
|
6
|
Plasminogen activator inhibitor-type I gene deficient mice show reduced influx of neutrophils in ventilator-induced lung injury. Crit Care Res Pract 2011; 2011:217896. [PMID: 21789277 PMCID: PMC3140778 DOI: 10.1155/2011/217896] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2011] [Revised: 05/15/2011] [Accepted: 05/17/2011] [Indexed: 01/11/2023] Open
Abstract
Ventilator-induced lung injury (VILI) is associated with inhibition of the fibrinolytic system secondary to increased production of plasminogen activator inhibitor- (PAI-)1. To determine the role of PAI-1 on pulmonary coagulopathy and inflammation during mechanical ventilation, PAI-1 gene-deficient mice and their wild-type littermates were anesthetized (control), or anesthetized, tracheotomized and subsequently ventilated for 5 hours with either low tidal volumes (LVT) or high tidal volumes (HVT). VILI was assessed by pulmonary coagulopathy, lung wet-to-dry ratios, total protein level in bronchoalveolar lavage fluid, neutrophil influx, histopathology, and pulmonary and plasma cytokine levels. Ventilation resulted in pulmonary coagulopathy and inflammation, with more injury following ventilation with HVT as compared to LVT. In PAI-1 gene-deficient mice, the influx of neutrophils in the pulmonary compartment was attenuated, while increased levels of pulmonary cytokines were found. Other endpoints of VILI were not different between PAI-1 gene-deficient and wild-type mice. These data indicate that a defect fibrinolytic response attenuates recruitment of neutrophils in VILI.
Collapse
|
7
|
Trudel D, Fradet Y, Meyer F, Harel F, Têtu B. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 2008; 39:731-9. [DOI: 10.1016/j.humpath.2007.09.021] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2007] [Revised: 08/30/2007] [Accepted: 09/26/2007] [Indexed: 10/22/2022]
|
8
|
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia 2007; 9:927-37. [PMID: 18030361 DOI: 10.1593/neo.07544] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2007] [Revised: 09/04/2007] [Accepted: 09/07/2007] [Indexed: 11/18/2022] Open
Abstract
Novel inhibitors of the urokinase-mediated plasminogen (plg) activation system are potentially of great clinical benefit as anticancer treatments. Using phage display, we identified DX-1000 a tissue factor pathway inhibitor-derived Kunitz domain protein which is a specific high-affinity inhibitor of plasmin (pln) (K(i) = 99 pM). When tested in vitro, DX-1000 blocks plasmin-mediated pro-matrix metalloproteinase-9 (proMMP-9) activation on cells and dose-dependently inhibits tube formation, while not significantly affecting hemostasis and coagulation. However, this low-molecular weight protein inhibitor ( approximately 7 kDa) exhibits rapid plasma clearance in mice and rabbits, limiting its potential clinical use in chronic diseases. After site-specific PEGylation, DX-1000 retains its activity and exhibits a decreased plasma clearance. This PEGylated derivative is effective in vitro, as well as potent in inhibiting tumor growth of green fluorescent protein (GFP)-labeled MDA-MB-231 cells. 4PEG-DX-1000 treatment causes a significant reduction of urokinase-type plasminogen activator (uPA) and plasminogen expressions, a reduction of tumor proliferation, and vascularization. 4PEG-DX-1000 treatment significantly decreases the level of active mitogen-activated protein kinase (MAPK) in the primary tumors and reduces metastasis incidence. Together, our results demonstrate the potential value of plasmin inhibitors as therapeutic agents for blocking breast cancer growth and metastasis.
Collapse
|
9
|
Woodward JKL, Holen I, Coleman RE, Buttle DJ. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. Bone 2007; 41:912-27. [PMID: 17945547 DOI: 10.1016/j.bone.2007.07.024] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2007] [Revised: 07/18/2007] [Accepted: 07/31/2007] [Indexed: 10/22/2022]
Abstract
Tumour-induced bone disease is a common clinical feature of advanced breast and prostate cancer and is associated with considerable morbidity for the affected patients. Our understanding of the molecular mechanisms underlying the development of bone metastases is incomplete, but proteolytic enzymes are implicated in a number of processes involved in both bone metastasis and in normal bone turnover, including matrix degradation, cell migration, angiogenesis, tumour promotion and growth factor activation. Malignant as well as non-malignant cells in the primary and secondary sites express these enzymes, the activity of which may be regulated by soluble factors, cell- or matrix-associated components, as well as a number of cell signalling pathways. A number of secreted and cell surface-associated proteolytic enzymes are implicated in tumour-induced bone disease, including the matrix metalloproteinases, lysosomal cysteine proteinases and plasminogen activators. This review will introduce the role of proteolytic enzymes in normal bone turnover and give an overview of the studies in which their involvement and regulation in the development of bone metastases in breast and prostate cancer has been described. The results from trials involving protease inhibitors in clinical development will also be briefly discussed.
Collapse
Affiliation(s)
- Julia K L Woodward
- Academic Unit of Clinical Oncology, D Floor, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
| | | | | | | |
Collapse
|
10
|
Florent JC, Monneret C. Doxorubicin Conjugates for Selective Delivery to Tumors. Top Curr Chem (Cham) 2007; 283:99-140. [DOI: 10.1007/128_2007_12] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/07/2023]
|
11
|
Kumi-Diaka JK, Hassanhi M, Merchant K, Horman V. Influence of genistein isoflavone on matrix metalloproteinase-2 expression in prostate cancer cells. J Med Food 2007; 9:491-7. [PMID: 17201635 DOI: 10.1089/jmf.2006.9.491] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
We investigated the expression of matrix metalloproteinase (MMP)-2 in human LNCaP and PC3 prostate cancer cell lines in response to genistein exposure. Initially we studied the phytosensitivity of the cells to genistein using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay to determine percentage cell viability/inhibition and the terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end-labeling apoptosis assay to assess the type of cell death. The results revealed that genistein inhibited growth and proliferation in both PC3 (hormone-dependent) and LNCaP (hormone-independent) prostate cancer cell lines, that there was no significant difference in sensitivity to genistein between PC3 and LNCaP cells, and that the effect of genistein on the cells was dose- and time-dependent. The results also revealed that inhibition of cell growth in both PC3 and LNCaP cells was predominantly due to apoptotic cell death. These results were consistent with data in previous studies. This was followed by determination of the MMP-2 profile in response to genistein treatment. The results indicated a significant dose- and time-dependent inhibition of MMP-2 expression levels in both cells, with a highly significant negative correlation between MMP-2 levels and concentration of genistein. This is of phytotherapeutic significance in view of the pivotal role of MMP-2 expression in the pathogenesis of prostate cancer. Increasing expression of MMPs has been identified in many human cancers, including prostate cancer. Our findings indicate that genistein could be a potent therapeutic inhibitor of MMP-2 in line with current concepts of targeted treatment.
Collapse
Affiliation(s)
- J K Kumi-Diaka
- Department of Biological Sciences, Schmidt College of Science, Florida Atlantic University at Davie, Davie, FL 33314, USA.
| | | | | | | |
Collapse
|
12
|
Rio MC. From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. Biochimie 2005; 87:299-306. [PMID: 15781316 DOI: 10.1016/j.biochi.2004.11.016] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2004] [Accepted: 11/23/2004] [Indexed: 01/14/2023]
Abstract
Stromelysin-3 (ST3) overexpression is associated with poor patient clinical outcome in numerous carcinomas. The ST3 is expressed by peritumoral fibroblast-like cells. Review of the literature shows that ST3 is an active partner of cancer cells along the whole natural cancer history, and is essential for optimal tumor development as it reduces death of cancer cells invading adjacent connective tissues at the primary tumor site. Paradoxically, ST3 lowers metastasis development in vivo in mice. However, this beneficial effect does not counterbalance the deleterious anti-apoptotic function of ST3.
Collapse
Affiliation(s)
- M C Rio
- Institut de génétique et de biologie moléculaire et cellulaire (IGBMC), CNRS/Inserm U184/ULP BP 163, 67404 Illkirch cedex, CU de Strasbourg, France.
| |
Collapse
|
13
|
Maillard C, Jost M, Rømer MU, Brunner N, Houard X, Lejeune A, Munaut C, Bajou K, Melen L, Dano K, Carmeliet P, Fusenig NE, Foidart JM, Noel A. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia 2005; 7:57-66. [PMID: 15720817 PMCID: PMC1490321 DOI: 10.1593/neo.04406] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Angiogenesis and tumor expansion are associated with extracellular matrix remodeling and involve various proteases such as the plasminogen (Plg)/plasminogen activator (PA) system. Recently, several experimental data have implicated the plasminogen activator inhibitor-1 (PAI-1) in tumor angiogenesis in murine systems. However, little is known about PAI-1 functions in human skin carcinoma progression. By generating immunodeficient mice (in Rag-1-/- or nude background) deleted for PAI-1 gene (PAI-1-/-), we have evaluated the impact of host PAI-1 deficiency on the tumorigenicity of two malignant human skin keratinocyte cell lines HaCaT II-4 and HaCaT A5-RT3 forming low-grade and high-grade carcinomas, respectively. When using the surface transplantation model, angiogenesis and tumor invasion of these two cell lines are strongly reduced in PAI-1-deficient mice as compared to the wild-type control animals. After subcutaneous injection in PAI-1-/- mice, the tumor incidence is reduced for HaCaT II-4 cells, but not for those formed by HaCaT A5-RT3 cells. These data indicate that PAI-1 produced by host cells is an important contributor to earlier stages of human skin carcinoma progression. It exerts its tumor-promoting effect in a tumor stage-dependent manner, but PAI-1 deficiency is not sufficient to prevent neoplastic growth of aggressive tumors of the human skin.
Collapse
Affiliation(s)
- Catherine Maillard
- Laboratory of Tumor and Development Biology, CRCE, CBIG, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège B-4000, Belgium
| | - Maud Jost
- Laboratory of Tumor and Development Biology, CRCE, CBIG, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège B-4000, Belgium
| | - Maria Unni Rømer
- Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, Copenhagen DK 2100, Denmark
| | - Nils Brunner
- Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, Copenhagen DK 2100, Denmark
| | - Xavier Houard
- Laboratory of Tumor and Development Biology, CRCE, CBIG, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège B-4000, Belgium
| | - Annabelle Lejeune
- Laboratory of Tumor and Development Biology, CRCE, CBIG, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège B-4000, Belgium
| | - Carine Munaut
- Laboratory of Tumor and Development Biology, CRCE, CBIG, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège B-4000, Belgium
| | - Khalid Bajou
- Laboratory of Tumor and Development Biology, CRCE, CBIG, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège B-4000, Belgium
| | - Laurence Melen
- Laboratory of Tumor and Development Biology, CRCE, CBIG, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège B-4000, Belgium
| | - Keld Dano
- Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, Copenhagen DK 2100, Denmark
| | - Peter Carmeliet
- Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven B-3000, Belgium
| | - Norbert E Fusenig
- Division of Carcinogenesis and Differentiation, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany
| | - Jean Michel Foidart
- Laboratory of Tumor and Development Biology, CRCE, CBIG, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège B-4000, Belgium
| | - Agnès Noel
- Laboratory of Tumor and Development Biology, CRCE, CBIG, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège B-4000, Belgium
| |
Collapse
|
14
|
Oltenfreiter R, Staelens L, Lejeune A, Dumont F, Frankenne F, Foidart JM, Slegers G. New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents. Nucl Med Biol 2004; 31:459-68. [PMID: 15093816 DOI: 10.1016/j.nucmedbio.2003.10.013] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Several studies have demonstrated a positive correlation between tumor progression and expression of extracellular proteinases such as matrix metalloproteinases (MMPs). MMP-2 and MMP-9 have become attractive targets for cancer research because of their increased expression in human malignant tumor tissues of various organs, providing a target for medical imaging techniques. Radioiodinated carboxylic and hydroxamic MMP inhibitors 2-(4'-[(123)I]iodo-biphenyl-4-sulfonylamino)-3-(1H-indol-3-yl)-propionic acid (9) and 2-(4'-[(123)I]iodo-biphenyl-4-sulfonylamino)-3-(1H-indol-3-yl)-propionamide (11) were synthesized by electrophilic aromatic substitution of the tributylstannyl derivatives and resulted in radiochemical yields of 60% +/- 5% (n = 3) and 70% +/- 5% (n = 6), respectively. In vitro zymography and enzyme assays showed high inhibition capacities of the inhibitors on gelatinases. In vivo biodistribution showed no long-term accumulation in organs and the possibility to accumulate in the tumor. These results warrant further studies of radioiodinated carboxylic and hydroxamic MMP inhibitor tracers as potential SPECT tumor imaging agents.
Collapse
Affiliation(s)
- Ruth Oltenfreiter
- Department of Radiopharmacy, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium.
| | | | | | | | | | | | | |
Collapse
|
15
|
Denys H, De Wever O, Nusgens B, Kong Y, Sciot R, Le AT, Van Dam K, Jadidizadeh A, Tejpar S, Mareel M, Alman B, Cassiman JJ. Invasion and MMP expression profile in desmoid tumours. Br J Cancer 2004; 90:1443-9. [PMID: 15054469 PMCID: PMC2409678 DOI: 10.1038/sj.bjc.6601661] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Desmoid tumours are locally invasive soft tissue tumours in which β-catenin mediated TCF-dependent transcription is activated. The role of soluble factors secreted by the myofibroblastic desmoid tumour, which could stimulate tumour invasiveness, was investigated. Using collagen gel invasion assays, the presence of factors stimulating invasion in desmoid conditioned media (CM) could be established. Since matrix metalloproteinases (MMPs) have been implicated in the process of tumoral invasion, the expression levels of the MMP family members were evaluated. Quantitative reverse transcription–PCR was used to determine the expression levels of MMP1, MMP2, MMP3, MMP7, MMP11, MMP12, MMP13, MMP14 and the inhibitors TIMP1, TIMP2 and TIMP3. Besides overexpression of MMP7, a known TCF-dependent target gene, a striking upregulation of the expression levels of MMP1, MMP3, MMP11, MMP12 and MMP13 in desmoid tumours, compared to unaffected fibroblasts from the same patients, was found. Treating the CM of desmoids with a synthetic and a physiologic MMP inhibitor reduced the invasion-stimulating capacity of the desmoid CM by approximately 50%. These results suggest the involvement of soluble factors, released by the desmoid cells, in stimulating invasion and implicate the MMPs as facilitators of invasion.
Collapse
Affiliation(s)
- H Denys
- Center for Human Genetics, University of Leuven, Leuven, Herestraat 49, B-3000 Leuven, Belgium
| | - O De Wever
- Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine, Ghent University Hospital, De Pintelaan 185, B-9000, Belgium
| | - B Nusgens
- Laboratory of Connective Tissues Biology, Tour de Pathologie, University of Liège, Sart Tilman, Belgium
| | - Y Kong
- The Program in Developmental Biology, The Hospital for Sick Children and the University of Toronto, 555 University Avenue, Toronto, Ontario, Canada M5G1X8
| | - R Sciot
- Laboratory of Morphology and Molecular Pathology, University of Leuven, Minderbroedersstraat 12, B-3000 Leuven, Belgium
| | - A-T Le
- The Program in Developmental Biology, The Hospital for Sick Children and the University of Toronto, 555 University Avenue, Toronto, Ontario, Canada M5G1X8
| | - K Van Dam
- Center for Human Genetics, University of Leuven, Leuven, Herestraat 49, B-3000 Leuven, Belgium
| | - A Jadidizadeh
- Center for Human Genetics, University of Leuven, Leuven, Herestraat 49, B-3000 Leuven, Belgium
| | - S Tejpar
- Center for Human Genetics, University of Leuven, Leuven, Herestraat 49, B-3000 Leuven, Belgium
| | - M Mareel
- Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine, Ghent University Hospital, De Pintelaan 185, B-9000, Belgium
| | - B Alman
- The Program in Developmental Biology, The Hospital for Sick Children and the University of Toronto, 555 University Avenue, Toronto, Ontario, Canada M5G1X8
| | - J-J Cassiman
- Center for Human Genetics, University of Leuven, Leuven, Herestraat 49, B-3000 Leuven, Belgium
- Center for Human Genetics, University of Leuven, Campus Gasthuisberg, Herestraat 49, Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail:
| |
Collapse
|
16
|
Devy L, de Groot FMH, Blacher S, Hajitou A, Beusker PH, Scheeren HW, Foidart JM, Noël A. Plasmin‐activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity. FASEB J 2004; 18:565-7. [PMID: 14734647 DOI: 10.1096/fj.03-0462fje] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
To generate doxorubicin (Dox) specifically at the tumor site, the chemotherapeutic agent was incorporated into a prodrug by linkage to a peptide specifically recognized by plasmin, which is overproduced in many cancers. ST-9905, which contains an elongated self-elimination spacer, is activated more rapidly in vitro by plasmin than is ST-9802. Prodrug activation in vitro depended on the level of urokinase produced by tumor cells and was inhibited by aprotinin, a plasmin inhibitor. Comparison of equimolar concentrations of ST-9905, ST-9802, and Dox in EF43.fgf-4 and MCF7 models revealed that both prodrugs, in sharp contrast to Dox, displayed antiproliferative and antiangiogenic activities without discernible toxicity. Although MCF7 cells are poor urokinase producers in vitro, prodrug efficacy in this model may be explained by production of plasmin by tumor-infiltrating host cells. Mice treated with equitoxic concentrations (maximum tolerated doses) of prodrugs showed 100% survival and negligible body weight loss, in contrast to results after Dox treatment. ST-9905 was substantially more effective than ST-9802 and induced similar tumor growth inhibition as Dox but without apparent toxicity. This finding may be explained by the elongated spacer, which facilitates enzymatic prodrug activation. These data validate both the use of elongated spacers in vivo and the concept of targeting anticancer prodrugs to tumor-associated plasmin.
Collapse
Affiliation(s)
- Laetitia Devy
- Laboratory of Tumor and Developmental Biology, University of Liège, Tour de Pathologie (B23), Sart-Tilman, B-4000 Liège, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Rijneveld AW, Florquin S, Bresser P, Levi M, De Waard V, Lijnen R, Van Der Zee JS, Speelman P, Carmeliet P, Van Der Poll T. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102:934-9. [PMID: 12702502 DOI: 10.1182/blood-2003-01-0227] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Urokinase-type plasminogen activator (uPA) and its receptor uPAR are components of the fibrinolytic system and are important for an adequate immune response to respiratory tract infection, in part through their role in the migration of inflammatory cells. PA inhibitor-1 (PAI-1) is the predominant inhibitor of soluble and receptor-bound uPA. To determine the role of PAI-1 in host defense against pneumococcal pneumonia, the following studies were performed: (1) Patients with unilateral community-acquired pneumonia demonstrated elevated PAI-1 concentrations together with decreased PA activity in bronchoalveolar lavage fluid (BALF) obtained from the infected, but not from the contralateral, site. (2) Mice with Streptococcus pneumoniae pneumonia displayed elevated PAI-1 protein and mRNA levels in their lungs. (3) PAI-1 gene-deficient mice, however, had an unaltered immune response to pneumococcal pneumonia, as measured by cell recruitment into lungs, bacterial outgrowth, and survival. Furthermore, plasminogen-gene-deficient mice also had an unremarkable defense against pneumococcal pneumonia. These data indicate that pneumonia is associated with inhibition of the fibrinolytic system at the site of the infection secondary to increased production of PAI-1; an intact fibrinolytic response is not required for an adequate host response to respiratory tract infection, however, suggesting that the previously described role of uPA and uPAR are restricted to their function in cell migration.
Collapse
Affiliation(s)
- Anita W Rijneveld
- Academic Medical Center, University of Amsterdam, F4-222, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|